🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations Dr. Robert Saddawi-Konefka Robert S-K⁩ for his work analyzing the cancer immune migratome during immunoradiotherapy, revealing a crucial role for an activated population of CCR7+ dc’s & support for lymphatic-preserving SBRT + CPI to optimize response. #AACR25

Adoptive cellular therapy is one of the pillars of our clinical & research programs Providence cancer institute, including this in house product being developed Earle A. Chiles Research Institute. Proud of the work our teams are doing to #FinishCancer with the power of the immune system. AgonOx

“It’s really exciting. It’s a new frontier for our patients.” Ravi Uppaluri, MDPhD of Dana-Farber discussed data from KEYNOTE-689 trial that showed KEYTRUDA (pembrolizumab) significantly extended EFS for patients with advanced HNSCC. AACR Brigham and Women's Hospital Harvard Medical School bit.ly/3YPEsdE

Great to be ⁦AHNS⁩ Annual meeting. Watch for the Immunotherapy session on Wed in which ⁦Chiles Research Institute⁩ IO Fellow Robert Herman will present updated survival from our Ph1 NIRT study. In addition, I will present data from KN689 during the evening sessions at 6pm!

If you are attending AHNS, please join Dr. Stephen Lai & me this evening (Wed) in Celestin E at 6:15pm for updates on NRG Oncology HN006 AND to hear PRACTICE CHANGING data from Keynote 689, the Ph3 trial of perioperative pembrolizumab recently presented AACR by Ravi Uppaluri, MDPhD

Adjuvant Cemiplimab better than Placebo in High-Risk Cutaneous SCC, giving more options for patients. Given that KN630 was negative in a similar, but not identical study group (c-post has higher risk pts), an important lesson in trial design. ⁦NEJM⁩ nejm.org/doi/full/10.10…

Delighted to present path response from our Neoadjuvant ImmunoRadioTherapy (NIRT-2) trial in pts w HPV- HNSCC ASCO mPR=71% pCR=29% Downstaging=67% Omission of adjuvant RT=83% Surgical de-escalation=50% Earle A. Chiles Research Institute UCSD Health Moores Cancer Center COE Joseph Califano UCSD Cancer #ASCO25 meetings.asco.org/abstracts-pres…

This work on DARK MATTER represents a real shift in thinking about which antigens are important in anti-tumor immune responses and is a rapidly evolving field within tumor immunology. Proud of our experts from Earle A. Chiles Research Institute, Bernie Fox & Rom Leidner for helping to lead it.

Boom!💥 ⁦FDA⁩ approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma, ushering in a new standard of care for the first time in decades. fda.gov/drugs/resource…

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery + risk adapted adjuvant therapy. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS.ascopubs.org/doi/10.1200/JC…

Here it is! KEYNOTE-689 primary publication online now NEJM. It’s been an incredible journey with DAdkins Siteman Cancer Center @WUSM. All started in early 2010s / now with U.S. FDA approval and a new standard of care! Dana-Farber News Brigham and Women's Hospital Brigham and Women’s Department of Surgery

nejm.org/doi/full/10.10…

⁦Journal for ImmunoTherapy of Cancer⁩ vision: Opportunities for deeper understanding of anti-tumor activity, toxicity & resistance to optimize cancer immunotherapy. Great work from Society for Immunotherapy of Cancer⁩ visionaries including our own Dr. Will Redmond. ⁦Earle A. Chiles Research Institute ⁦ jitc.bmj.com/content/13/6/e…

Congratulations to Dr. Michael Gough & Team nature. This work leverages the use of mathematical modeling to explore the complexity of immune responses between individuals & of an explant system as a tool to rapidly evaluate patient responses. nature.com/articles/s4169…

New Study published in ⁦Nature Portfolio⁩: @Providence whole genome sequencing program shows transformative potential for population health and provides a roadmap for the early detection and prevention of cancer ⁦Earle A. Chiles Research Institute⁩ ⁦ blog.providence.org/national-news/…

Kolby and Kinslee raised over $100 for cancer research⁩ on behalf of their granddad, Mark Williams, who is 17 year survivor of metastatic melanoma, treated with immunotherapy ⁦Providence⁩. I think that must be the best lemonade ever made. Thank you! ❤️🙏🍋⁦